FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington, D.C. 20549

## **OMB APPROVAL**

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(b) of the Investment Company Act of 1940

											.,									
	nd Address of		2. Issuer Name and Ticker or Trading Symbol Decibel Therapeutics, Inc. [ DBTX ]										Relationship of Reporting Person(s) to Issuer (Check all applicable)							
REGENERON PHARMACEUTICALS, INC.						Sector Increpences, inc. [ DDIN ]									Director		X	10% Ov	/ner	
												Officer (gi below)	ve title		Other (s below)	pecify				
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 02/17/2021										•			ŕ		
REGENERON PHARMACEUTICALS, INC. 777 OLD SAW MILL RIVER ROAD																				
						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) TARRYTOWN NY 10591															X Form filed by One Reporting Person Form filed by More than One Reporting Person					
TARKTIOWN IVI			10331												Form filed	i by More	ınan O	пе кероп	ng Person	
(City)	(	State)	(Zip)																	
			Table I - Non-	Deriva	ative	Sec	curities A	cqui	ired, I	Disp	osed	of, or	Ben	eficially O	wned					
Dat					2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year		Code (Instr.		4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 a						6. Owr Form: (D) or (I) (Ins	Direct Indirect tr. 4)	7. Nature of ndirect Beneficial Ownership Instr. 4)	
									Code	v	Amount		A) or D)	Price	(Instr. 3 and				IIISU. 4)	
Common Stock 02/17					7/2021			С		2,097,	314	A	(1)	2,097,314(1)			D			
			Table II - D (e				ırities Acc s, warrant								ned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. N Deri Sec Acq Disp	lumber of ivative surities quired (A) or posed of (D) tr. 3, 4 and	6. D	6. Date Exercisable an Expiration Date (Month/Day/Year)			7. Title Securit	and A ies Ur ive Se	amount of nderlying ecurity (Instr.	8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securitic Benefici Owned Followir Reporte Transac	ve es ially ng d	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exe	e ercisable		cpiration ate	Title	N	mount or umber of hares		(Instr. 4)				
Series B Preferred Stock	(1)	02/17/2021		С			12,500,000		(1)		(1)	Commo		989,299(1)	\$0	0		D		
Series C Preferred	(1)	02/17/2021		С			14,000,000		(1)		(1)	Commo		,108,015 <sup>(1)</sup>	\$0	0		D		

## Explanation of Responses:

1. The Series B Preferred Stock and Series C Preferred Stock converted into shares of common stock of Decibel Therapeutics, Inc. ("Decibel") on an approximately one-for-0.079 basis upon the closing of Decibel's initial public offering, which occurred on February 17, 2021. The Series B Preferred Stock and Series C Preferred Stock had no expiration date. The reported number of shares of underlying common stock and the conversion ratio give effect to Decibel's one-for-5.3 reverse stock split, which became effective on February 5, 2021.

/s/ Richard Gluckselig, Executive 02/18/2021

**Director**, Assistant General

Counsel and Assistant Secretary

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.